Spherium Biomed announced the completion of its Phase I/IIa clinical trial of Mucomel® for the prevention...

Asphalion, scientific and regulatory affairs consultancy, has opened its third office in Madrid managed by Dr André Mota...

Avinent has posted several research studies on its website that wereconducted in collaboration with renowned scientists and...

Hartmann presented its latest advances in negative-pressure wound therapy (NPWT)...

Compliance Services, a regulatory affairs consultancy for the health sector and member of CataloniaBio & HealthTech...

Eleven Catalan companies from the 3D printing and medical devices sectors participated in a mission to Boston (Massachusetts, United States), from 16 to 19 April, organised by the Government of Catalonia (through ACCIÓ) and the Catalonia Trade and Investment Office in Boston, with collaboration from CataloniaBio & HealthTech.

Over the four-day mission, Avinent, Diopma, Mastertec, Neos Surgery, Servocad Microtronics, Tractivus and Ventura Medical, plus the Institute for Bioengineering of Catalonia (IBEC), Hospital Clinic, Althaia Foundation and Fira de Barcelona, met with companies and organisations including Massachusetts General Hospital, Tufts Medical Center, Boston Scientific, Weitz Laboratory at Harvard University and Johnson ...

A delegation of eight Catalan companies from the biomedicine and health arena, most CataloniaBio & HealthTech members...

Reig Jofre has announced a €30 million investment and the triplication of the productive capacity of its Barcelona plant...

Palex Medical, a CataloniaBio & HealthTech member company, will be the exclusive distributor in Spain and...

AB-Biotics, a CataloniaBio & HealthTech member company, has closed a deal with the Japan-based Kaneka...

Vytrus Biotech, a CataloniaBio & HealthTech member company, has successfully closed the €1-million round...

Devicare and nine leading hospitals in urology have started the pioneering international "Double J" study to...

Grifols, member of CataloniaBio & HealthTech, makes inroads in its research efforts to find a treatment for Alzheimer...

Pharmaphenix, member of CataloniaBio & HealthTech and headquartered in the Barcelona Science Park, is celebrating...

Archivel Farma, owner of the therapeutic vaccine targeting tuberculosis Ruti®, and Laboratorios Silanes, one of the major Mexican pharmaceutical companies, have signed a collaboration agreement for the clinical development and commercialization of the vaccine in Mexico.

The pharmaceutical company Reig Jofre strengthens its commitment to open innovation and the development of injectable and freeze-dried products with the creation of the joint venture Syna Therapeutics, for the development of biopharmaceutical products in the field of biosimilar products and innovative molecules.

Mario Rovirosa has been named CEO of pharmaceutical company Ferrer and will take up this position on 1 April. Rovirosa is taking over for Jordi Ramentol that will continue to have ties to Ferrer as a member of the company’s board of directors.  

Una setantena d'emprenedors i professionals de l'àmbit de la biomedicina i la salut van participar a la jornada sobre les oportunitats internacionals en compra pública d’innovació (CPI) organitzada per ACCIÓ i CataloniaBio & HealthTech, el dia 6 de març a Barcelona.

The latest edition of the Fem Talent Fòrum recognised Dr Judit Anido, CEO of Mosaic Biomedicals and member of the board at CataloniaBio & HealthTech, in the emerging talent category. Anido is the co-founder, with Dr Joan Seoane and Dr Josep Baselga, of Barcelona-based biotechnology firm Mosaic Biomedicals, which is developing personalised cancer treatments. 

Another company in the biomedicine and healthcare arena, ProteoDesign, was a runner-up in the organisation category. The awards were given out in a ceremony held at Barcelona Activa Advanced Industry Park with more than 400 people in attendance. The Fem Talent awards aim to recognise ...

Biotechnology company Thrombotargets has opened a round of funding looking to raise €5.5 million to complete development of its topical treatment for haemorrhages during surgery. The drug, known as TT-173, has begun phase III clinical trials. The Castelldefels-based company has been working on this product for 15 years now.

The main shareholder in Thrombotargets is Biotech Angels and the chairman of the board of directors is perfume businessman Ramón Béjar. The board of directors  is formed by Ignasi Miquel, Pilar Sánchez i Jesús Murat. The company was started in 2005, developing the BioplatformScreen platform used to screen molecules.  ...